829 related articles for article (PubMed ID: 20452823)
1. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
3. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
Ning H; Zhou H; Ren J; Zhou G; Yang N; Wang Z; Yuan C; Tian Z; Chen J; Shen L; Zheng H; Zhao Y; Wang H; Liu W; Liu Z
J Transl Med; 2022 Aug; 20(1):357. PubMed ID: 35962349
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
[TBL] [Abstract][Full Text] [Related]
8. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K
Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901
[TBL] [Abstract][Full Text] [Related]
10. Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.
Gu SC; Zhou J; Ye Q; Yuan CX
J Integr Med; 2021 Mar; 19(2):120-128. PubMed ID: 33446472
[TBL] [Abstract][Full Text] [Related]
11. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Schrag A; Carroll C; Duncan G; Molloy S; Grover L; Hunter R; Brown R; Freemantle N; Whipps J; Serfaty MA; Lewis G
BMC Neurol; 2022 Dec; 22(1):474. PubMed ID: 36510237
[TBL] [Abstract][Full Text] [Related]
12. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
[TBL] [Abstract][Full Text] [Related]
13. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
[TBL] [Abstract][Full Text] [Related]
14. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA
Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
Lewis G; Duffy L; Ades A; Amos R; Araya R; Brabyn S; Button KS; Churchill R; Derrick C; Dowrick C; Gilbody S; Fawsitt C; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Khan N; Lanham P; Pervin J; Peters TJ; Riozzie D; Salaminios G; Thomas L; Welton NJ; Wiles N; Woodhouse R; Lewis G
Lancet Psychiatry; 2019 Nov; 6(11):903-914. PubMed ID: 31543474
[TBL] [Abstract][Full Text] [Related]
17. The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment.
Dogan B; Akyol A; Memis CO; Sair A; Akyildiz U; Sevincok L
Psychogeriatrics; 2019 Jan; 19(1):73-79. PubMed ID: 30141277
[TBL] [Abstract][Full Text] [Related]
18. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
[TBL] [Abstract][Full Text] [Related]
19. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
Xiang W; Sun YQ; Teoh HC
Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
